Dantrolene Sodium
13 NDCs across 6 manufacturers|13 Generic,0 Brand
Dantrolene Sodium is used to treat cerebral infarction, cerebral palsy, malignant hyperthermia, multiple sclerosis, muscle spasticity and neuroleptic malignant syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Mar 1, 2005. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $4 million on Dantrolene Sodium across 43,000 claims for 6,679 beneficiaries.
Dantrolene Sodium is available as 13 NDCs from 6 manufacturers (13 generic, 0 brand), with NADAC prices from $0.43 to $0.99 per EA — the most expensive product costs about 2.3× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
13
13G / 0B
Manufacturers
6
competing in market
Price Spread
$0.43 – $0.99
per EA
7d Activity
avg -1.1% WoW · of 13 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
6 manufacturers producing DANTROLENE SODIUM
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
DANTROLENE SODIUM 100 MG CAP | $0.9911 per EA | +9.91% |
DANTROLENE SODIUM 100 MG CAP | $0.9911 per EA | +9.91% |
DANTROLENE SODIUM 100 MG CAP | $0.9911 per EA | +9.91% |
DANTROLENE SODIUM 25 MG CAP | $0.7194 per EA | — |
DANTROLENE SODIUM 50 MG CAP | $0.5739 per EA | -3.61% |
DANTROLENE SODIUM 50 MG CAP | $0.5739 per EA | -3.61% |
DANTROLENE SODIUM 50 MG CAP | $0.5739 per EA | -3.61% |
DANTROLENE SODIUM 25 MG CAP | $0.4304 per EA | -5.29% |
DANTROLENE SODIUM 25 MG CAP | $0.4304 per EA | -5.29% |
DANTROLENE SODIUM 25 MG CAP | $0.4304 per EA | -5.29% |
DANTROLENE SODIUM 25 MG CAP | $0.4304 per EA | -5.29% |
DANTROLENE SODIUM 25 MG CAP | $0.4304 per EA | -5.29% |
DANTROLENE SODIUM 25 MG CAP | $0.4304 per EA | -5.29% |
Frequently Asked Questions
What is Dantrolene Sodium used to treat?
Dantrolene Sodium is used to treat cerebral infarction, cerebral palsy, malignant hyperthermia, multiple sclerosis, muscle spasticity and neuroleptic malignant syndrome, per the National Library of Medicine's MED-RT classification.
When did Dantrolene Sodium become available as a generic?
FDA approved the first generic Dantrolene Sodium (ANDA) on Mar 1, 2005. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Dantrolene Sodium?
In 2024, Medicare Part D spent $4 million on Dantrolene Sodium across 43,000 claims for 6,679 beneficiaries.
How many Dantrolene Sodium products are on the market?
The Dantrolene Sodium drug market contains 13 NDCs from 6 manufacturers — 13 generic and 0 brand products.
What is the price range for Dantrolene Sodium?
NADAC reference prices for Dantrolene Sodium range from $0.4304 to $0.9911 per EA — the most expensive product costs about 2.3× the cheapest.
Which manufacturers make Dantrolene Sodium?
6 manufacturers list Dantrolene Sodium in NADAC. Ranked by number of NDCs, the largest are Amneal Pharmaceuticals of New York LLC (4), Endo USA Inc. (3), Elite Laboratories, Inc. (3), American Health Packaging (1), Major Pharmaceuticals (1).
How has the price of Dantrolene Sodium changed recently?
Over the past 7 days, 3 Dantrolene Sodium NDCs rose and 9 fell, with a market-wide average change of -1.1%.